GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » ROA %

ChromaDex (ChromaDex) ROA % : 0.84% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is ChromaDex ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ChromaDex's annualized Net Income for the quarter that ended in Dec. 2023 was $0.46 Mil. ChromaDex's average Total Assets over the quarter that ended in Dec. 2023 was $54.22 Mil. Therefore, ChromaDex's annualized ROA % for the quarter that ended in Dec. 2023 was 0.84%.

The historical rank and industry rank for ChromaDex's ROA % or its related term are showing as below:

CDXC' s ROA % Range Over the Past 10 Years
Min: -77.95   Med: -40.13   Max: -9.06
Current: -9.16

During the past 13 years, ChromaDex's highest ROA % was -9.06%. The lowest was -77.95%. And the median was -40.13%.

CDXC's ROA % is ranked better than
75.39% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs CDXC: -9.16

ChromaDex ROA % Historical Data

The historical data trend for ChromaDex's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex ROA % Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.95 -50.70 -56.40 -29.56 -9.06

ChromaDex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.38 -14.11 -16.39 -7.19 0.84

Competitive Comparison of ChromaDex's ROA %

For the Biotechnology subindustry, ChromaDex's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChromaDex's ROA % distribution charts can be found below:

* The bar in red indicates where ChromaDex's ROA % falls into.



ChromaDex ROA % Calculation

ChromaDex's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-4.938/( (54.057+54.964)/ 2 )
=-4.938/54.5105
=-9.06 %

ChromaDex's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.456/( (53.483+54.964)/ 2 )
=0.456/54.2235
=0.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


ChromaDex  (NAS:CDXC) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=0.456/54.2235
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.456 / 84.784)*(84.784 / 54.2235)
=Net Margin %*Asset Turnover
=0.54 %*1.5636
=0.84 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ChromaDex ROA % Related Terms

Thank you for viewing the detailed overview of ChromaDex's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus

A Letter from the ChromaDex Chief Executive Officer

By Business Wire Business Wire 02-21-2023